SCHEMBL2346101

SCHEMBL2346101

COC(=O)C(CN)(Cc1ccccc1)NC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA7 P43166 1/20 0.44
CA14 Q9ULX7 1/20 0.44
RECQL P46063 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP1A2 P05177 1/20 0.43
AKT1 P31749 3/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPK1 P28482 1/20 0.42
PTPRB P23467 2/20 0.42
ATM Q13315 1/20 0.41
KLK5 Q9Y337 2/20 0.40
IDO1 P14902 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPRA P18433 1/20 0.40
CTSS P25774 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2346109 1.00 CA12 (0.44) CA12CA1CA7CA14RECQL
SCHEMBL2343598 0.88 CA12 (0.45) CA12CA1CA7CA14RECQL
SCHEMBL2343596 0.88 CA12 (0.45) CA12CA1CA7CA14RECQL
SCHEMBL2712570 0.87 AKT1 (0.45) CA12CA1CA7CA14RECQL
Hydrochloric Acid SCHEMBL7429104 0.87 MAPK1 (0.41) CA12CA1CA7CA14RECQL
SCHEMBL6473387 0.85 MAPT (0.45) CA12CA1CA7CA14RECQL
SCHEMBL8219589 0.85 MAPT (0.45) CA12CA1CA7CA14RECQL
SCHEMBL8225007 0.84 MAPT (0.52) CA12CA1CA7CA14RECQL
SCHEMBL2711160 0.83 CA12 (0.50) CA12CA1CA7CA14RECQL
SCHEMBL2210445 0.82 CA12 (0.49) CA12CA1CA7CA14RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008315-B2 Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme Corp. (US) 2011-08-30 US disclosed
US-8008315-B2 Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme Corp. (US) 2011-08-30 US disclosed
US-7829597-B2 Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme, Inc. (US) 2010-11-09 US disclosed
US-20100210693-A1 BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Merck, Sharpe & Dohme Corp. 2010-08-19 US disclosed
US-20100210693-A1 BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Merck, Sharpe & Dohme Corp. 2010-08-19 US disclosed
EP-1673078-B1 BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO INC (US) 2008-05-28 EP disclosed
US-20060293380-A1 Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease MERCK SHARP & DOHME LLC 2006-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293380-A1 Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease BACE1, BACE2, PSEN1 CA12 2807/4885CA1 825/4885CA7 1708/4885
US-20100210693-A1 BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BACE1, BACE2, PSEN1 CA12 2866/4885CA1 843/4885CA7 1940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.